News & insights

In 2022, the CEPA team explored the potential impact of ten promising innovations that Unitaid may support during its 2023-27 strategic period, which could make a significant contribution to advancing global health targets. We modelled health outcomes across low and middle-income countries with and without each innovation under a wide range of plausible assumptions and scenarios to inform development of Unitaid’s Strategy and Investment Case.

The products we modelled included long-acting options for HIV pre-exposure prophylaxis; a urinary lateral flow test for quick and affordable TB screening; new tools for controlling malaria vectors through endectocide mass drug administration, spatial repellents, and dual-active-ingredient bed-nets; and five products for prevention and management of post-partum hemorrhage, and the detection of eclampsia during pregnancy.

We provided Unitaid with insights on the possible impacts of each innovation, key dependencies, their potential to contribute towards advancing global health targets, and the value that accelerating equitable access could bring.